GSK’s Q2 top-line growth came under pressure due to COVID-19-related disruptions, particularly in Vaccine, and destocking in the Pharmaceuticals and Consumer Healthcare segments. Rising investments in oncology and COVID-19-related treatments further impacted the bottom-line. Although recovery could be slow, as people avoid visits to physicians, the newer class of drugs in the Pharmaceutical segment could fuel growth in the near to mid-term. Pre-booking of COVID-19 vaccines has been enco
05 Aug 2020
Vaccine weighs on Q2
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Vaccine weighs on Q2
GSK plc (GSK:LON) | 1,588 -23.8 (-0.1%) | Mkt Cap: 65,831m
- Published:
05 Aug 2020 -
Author:
Rishabh Kochar -
Pages:
4
GSK’s Q2 top-line growth came under pressure due to COVID-19-related disruptions, particularly in Vaccine, and destocking in the Pharmaceuticals and Consumer Healthcare segments. Rising investments in oncology and COVID-19-related treatments further impacted the bottom-line. Although recovery could be slow, as people avoid visits to physicians, the newer class of drugs in the Pharmaceutical segment could fuel growth in the near to mid-term. Pre-booking of COVID-19 vaccines has been enco